The response to double-dose hepatitis B vaccination in patients with HIV

TURKEN M., KIŞ T. T., ATALAY S., KÖSE Ş.

THE EUROPEAN RESEARCH JOURNAL, vol.8, no.1, pp.31-36, 2022 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Article
  • Volume: 8 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.18621/eurj.822127
  • Journal Name: THE EUROPEAN RESEARCH JOURNAL
  • Journal Indexes: EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.31-36
  • Dokuz Eylül University Affiliated: No

Abstract

Objectives: Prevention of hepatitis B virus (HBV) infection is necessary for patients with human immunodeficiency virus (HIV), since co-infection is associated with increased in mortality. The aim of this study was to investigate response to double-dose HBV vaccine in patients with HIV. Methods: A total of 149 patients with HIV were retrospectively evaluated. Sixty-eight patients who were HBV seronegative and administered double-dose HBV vaccine were included in the study. According to anti HBs levels, patients were evaluated in three groups: < 10 mIU/mL, 10-100 mIU/mL and ≥ 100 mIU/mL. Age, sex, transmission route, smoking, alcohol-substance abuse, comorbidities, CD4+ T cells counts and HIV viral load were compared in three groups. Results: The rate of response to HBV vaccination (anti HBs ≥ 10 mIU/mL) was 69.1%. Age was statistically significantly higher in the anti HBs < 100 mIU/mL group than in the anti HBs >100 mIU/mL group. The level of anti HBs was statistically significantly lower in patients with a CD4+ T cell count < 200 cells/μL (< 100 mIU/mL). Conclusions: The use of high-dose vaccine is a necessity as well as revaccination to improve vaccine immunogenicity in patients with HIV. In our study, low CD4+ T lymphocyte count and older age were found to have a negative effect on vaccine response. Keywords: HIV, HBV, co-infection, HBV vaccination, response